HONG KONG – As Genor Biopharma Co. Ltd. prepares to move forward with clinical trials for biosimilar Remicade (infliximab, Johnson & Johnson) along a traditional regulatory pathway, regulators in China are still considering an approval pathway specific to biosimilars. While such a pathway would be welcome, it may not necessarily translate into faster approval times.